Interview with Fabian Dwyer, General Manager, IMS Health Australia
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Address: Suite 406, Kew Junction Tower, 89 High Street Kew, Vic 3101,Australia
Tel: +61 3 9455 1444
Web: http://www.imshealth.com.au/
With offices in Sydney, Melbourne and Auckland, IMS Health Australia is a trusted partner delivering solutions to local pharmaceutical and healthcare sectors.
IMS Health Australia captures information from a wide range of sources including pharmacies, hospitals, pharmaceutical wholesales, healthcare professionals, software suppliers and the pharmaceutical industry. This information is combined to give a complete picture of the market and is critical in business decisions such as assessing the impact of product launches or identifying new uses for existing therapies.
IMS Health Australia provides crucial insight into the pharmaceutical industry, healthcare manufacturers, distributors, government and healthcare agencies, academic institutions and research organizations. This information enables the development of medical education and information programs, rationale of the cost-effectiveness of drug therapies and evaluation of patient health outcomes in health policy decisions. This information is critical to both IMS Health Australia’s customers and supply partners and provides a clearer picture of the healthcare landscape.
IMS Health Australia is committed to servicing the information needs of the healthcare sector. IMS Health Australia offers a continuum of capabilities from information to analytics to consulting. With over 50 years experience and offices in more than 100 countries, IMS Health Australia is the leading source of global information for the pharmaceutical and healthcare industry.
Analytics, Research and development, Generics, Consulting
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
See our Cookie Privacy Policy Here
